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MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 6 4 5e6 5 1646There is a growing awareness of the importance of identifying
conditions that can contribute to translational cancer
research success (Pozen and Kline, 2011). A need to improve
performance is also a priority, in order to reduce the time
taken to translate successful innovations from the laboratory
into the clinic (Contopoulus-Ioannidis et al., 2008), and to take
observations made in clinical studies back to the lab for
further investigation or for the discovery of new biology. The
increasing cancer burden and the fact that the performance
of European cancer research could be considerably improved
were the underlying drives for the EU Sixth Frame Work Pro-
gramme (FP6) to fund clinical research for the first time
(Busquin, 2002).
The EurocanþPlus project (Eurocan plus report, 2008),
funded in October 2005 (FP6), carried out a comprehensive
analysis of European cancer research to identify barriers
that hampered collaboration between various stakeholders,
nationally as well as between European countries. One of
the main conclusions of this project was the need to
strengthen the collaboration between cancer research centres
in order to achieve critical mass and share the infrastructure
necessary for innovative translational cancer research. The
concept of a Comprehensive Cancer Centre (CCC) was consid-
ered of great importance, being the only organisational form
in which cancer treatment and care are closely integrated
with research and education and, therefore, optimal for trans-
lational research.
As a follow-up to the EurocanþPlus project, in 2011, the Eu-
ropean Commission (EC) funded the EurocanPlatform, which
brings together 23 European cancer research centres and 5
cancer organizations to structure translational cancer
research. The long-term goal of this platform is to create a sus-
tainable translational cancer research platform with the crit-
ical mass of expertise, resources, infrastructures, and
patient numbers that are needed to facilitate innovation and
improve performance in all areas of cancer research, particu-
larly translational research. Recently, six EurocanPlatform
centres established Cancer Core Europe (CCE) (Eggermont
et al., 2014) as a significant first step towards establishing
such platform (Eggermont et al., 2014; Celis and Ringborg,
2014).
As requested by the EC (Ringborg, 2008; Brown, 2009), a
work package was dedicated to developing a methodology to
quality assure and designate “CCCs of Excellence” that could
qualify for future European funding. Developing a methodol-
ogy for identifying and assessing CCCs of Excellence in trans-
lational research was one of its primary goals. Towards this
aim, we previously reported the steps that were taken to
develop a draft Excellence Designation System (EDS) (Rajan
et al., 2013). This included evidence from current literature
and a European stakeholder consensus exercise, covering a
2-year (2011e2013) period and involving researchers, man-
agers, clinicians and patient representatives from cancer in-
stitutions across Europe. Now, we describe a final EDS that
has been developed in collaboration between the EurocanPlat-
form and the European Academy of Cancer Sciences (EACS)
and that has been piloted with three European CCCs. Its rele-
vance for CCCs and translational research is discussed.
Translational research has rapidly evolved in the past
decade (Doroshow and Kummar, 2014) and numerousdefinitions currently exist (Woolf, 2008; Rajan et al., 2012).
However, only few cover the complete cancer research contin-
uum from bench to bedside and vice versa (Rajan et al., 2012).
One definition (National Institutes of Health, 2014) that does,
was put forward by the staff of the National Cancer Institute
(NCI) while working with Dr. Richard Klausner, it’s former
Director:
“Translational research uses knowledge of human biology to
develop and test the feasibility of cancer-relevant interventions
in humans OR determines the biological basis for observations
made in individuals with cancer or in populations at risk for can-
cer. The term “interventions” is used in its broadest sense to
include molecular assays, imaging techniques, drugs, biological
agents, and/or other methodologies applicable to the prevention,
early detection, diagnosis, prognosis, and/or treatment of can-
cer”(National Institutes of Health, 2014).
We present this perspective in three parts: (i) an introduc-
tion to the EDS that we piloted with 3 European CCCs (see
acknowledgement for composition of peer-review team), in
September 2014 at Helsinki University Central Hospital Cancer
Center, Cambridge Cancer Centre and The Netherlands Can-
cer Institute; (ii) a summary of the pilot results (see Table 1)
as well as the experiences of CCCs and the peer-reviewers
(Pozen and Kline, 2011) from taking part in the pilot; and (iii)
a discussion of the relevance of the system for translational
oncology and an overall conclusion.1. Excellence Designation System (EDS) in
translational research for CCCs
European CCCs already go through several assessments at the
national level. In addition, they undergo European/interna-
tional assessments such as the accreditation and designation
system developed by the Organization of European Cancer In-
stitutes (OECI). Hence, it was felt that the EDS should not rein-
vent the wheel nor add bureaucracy by creating a totally new
assessment system. So, it takes the existing national/interna-
tional assessments as a basis. The reason that the EDS criteria
are made descriptive is primarily that it builds on the OECI
accreditation & designation system and secondly that various
scientometric and quantitative analyses are already part of
both the OECI-system and other reviews. At present there is
no quantitative rating system for EDS as it was felt that expert
review is at present the best way to judge the excellent status
of translational research. The EDS covers only criteria that are
not included in the OECI standards for CCCs. The standards
related to inventory and core facilities exist in the OECI pro-
gramme and this information will be obtained from the OECI
designation report. Moreover, excellence can be found in
fields that do not necessarily overlap. European CCCs that
have an OECI CCC designation are eligible to apply to this pro-
gramme. However, balancing between maintaining a high
standard of the excellence program and allowing CCCs that
apply to have a fair chance at achieving the designation status
is a challenge. In the EurocanPlatform project the system is
meant to set criteria for entry in European Translational
Research platforms, which is considered for instance for
Table 1 e Pilot designation status of the 3 Comprehensive Cancer Centres and key findings.
Dimensions Helsinki University Central Hospital Cancer
Center
The Netherlands Cancer Institute Cambridge Cancer Centre
Pilot designation
status
Actual potential for excellence Excellent Excellent
Strengths or existing
excellence
-Small country with excellent global survival statistics
-Attracting the best people in the country
-Strong position in Nordic research
-Outstanding population-based registry
-Young centre with opportunity to embrace rapidly
evolving technologies and huge potential in precision
medicine
-General direction e open to change, translational
research and international collaborations
-Strong individual leaders in research (angiogenesis,
precision medicine, haematology)
-Bench to bedside & back programs
-Evidence of research reducing mortality
-PhDs and postdoctoral students very satisfied with the
work environment
-Extraordinary examples of deep translational science
based on mechanistic basic science in a continuum to
clinical care and back again particularly regarding
resistance mechanisms
-26% of patients on clinical trials
-Strong investigator-driven clinical trials with
biomarkers
-Three programs developing based on a decision by the
Translational Research Board: immunotherapy, image-
guided radiation therapy, precision medicine
-The model of twinning (pairing basic and clinical
scientists) is successful, based on the projects, the fact
that there are 39 MD-PhD students and 200 PhD students
e provides an exciting model and a third of publications
are generated from this mechanism
-Shared labs, monthly staff meetings, clinical rotations
for PhDs
-Open, strong and visionary new leadership for the
institute and candid views regarding ways to improve
the program
-National collaborations within the context of Centre for
Personalized Cancer Treatment are exciting and lead to
further opportunities for novel clinical trials
-Also allows for the development of biobanking and IT
-Extraordinary conduit between basic, translational and
clinical trials and back again to the laboratory
-Superb leadership in bringing in basic science
departments within the virtual cancer centre
-Exciting primary basic research leading to clinical trials
(BET, DNA repair) and clinically driven projects with
important implications for outcome-Barrett’s and
endoscopy studies and Breast
-Solid approach to innovation and creative
collaborations with pump priming projects, research
sessions for National Health Services staff and director’s
funds
-Impressive backing of clinician-scientist careers and
input to oncology research across training schemes-the
trainees were committed to hypothesis-based clinical
trials and have clinical support and protected time
-External networking within European partners with up
to 70,000 new patients per year for trials
-First approach to network within major UK Cancer
Centres with harmonization of trial and e-health
infrastructure
-Impressive 16e50% entry into trials across departments
and all histology
Opportunities for
further excellence
-Biobanking e annotation and real time acquisition of
samples-priority for sites.
-New money for high risk/high gain innovative
collaborations in house: has infrastructure but not
resources for novel collaborations; integrated neurology,
immunobiology, obesity should be integrated in cancer
-Improved relationship with university regarding
discovery: protect intellectual property
-Combination drugs testing
-More academic trials (proof of concept studies, First in
Human trials, testing drug resistance), phase IeII
Clinical trials network/opportunity to become a national
early phase center-need improved accrual e Biomarker
driven trials
-Selection of 3 cancer types; use of 3D cultures, patient
derived xenografts, genomics-precision medicine
-Increasing the time commitment to research for
clinician-scientists beyond 50%. Recognize it is a
priority; strong thrust in molecular pathology
-Efforts to engage basic cancer researchers in
translational cancer research where this is relevant and
possible. This should take into account that basic
research creates the foundation on which to build
translational research.
-Continue strong, new biological studies combining
radiotherapy research (especially image guided
radiation therapy) with basic and translational research
fields such as targeted agents, DNA repair,
immunotherapy and mechanistic studies regarding
tissue side effects.
-Transparent and branding approach (used by
Foundation) to practice-changing publications (i.e.
-Expectations from experts to excel in national and
international leadership in cancer research driving to
the clinic
-Unique opportunities from strengths (e.g. marry
genomics to imaging with respect to tumour
heterogeneity)
-Opportunities to marry strong immunobiology to
immunotherapy
-15% trials where the biology was discovered by the
cancer center (30% of investigator initiated)-should be
improved
-Consider resources for increased control over robust
biomarkers leading to increased patient stratification for
trials (e.g. using patient derived xenografts models to
test the DNA repair inhibiting studies)
-Have an integrated structure to supervise all the clinical
(continued on next page)
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MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 6 4 5e6 5 1648Cancer Core Europe (Eggermont et al., 2014; Celis and
Ringborg, 2014).
Ultimately it is expected that through this and other plat-
forms a league of excellent CCC’s will emerge that can act as
leaders in the field both for their peers as well as for, govern-
ments, the EU and various agencies.
To give each CCC flexibility to prove their excellence, ex-
perts agreed to begin the EDS process without a rating scale
and only to consider adopting it after broader implementation
and accumulation of sufficient and firm empirical data.
Experts/peer-reviewers decided not to define certain termi-
nology in the criteria (e.g. what are high risk/high-gain pro-
jects), as they wanted evidence of high-risk/high-reward
projects to come using a bottom-up approach rather than
pre-defining what the nature of those items should be.
The assessments were conducted with impartial evalua-
tion involving independent experts using existing reports
available in English and not older than 5 years. This allowed
the reviewers to check the validity, feasibility and relevance
of the excellence criteria, and to formulate questions (see
Supplementary file) to be addressed at the on-site meetings.
1. Articulation of a vision of the Cancer Centre’s philosophy,
scientific directions, and goals for the next 5 and 10 years;
and which projects and translational science studies are
expected to change the paradigms of clinical oncology.
2. Demonstration (with organisational data and publica-
tions) of at least three multidisciplinary programmes
that are being pursued in great depth from basic discovery
through pre-clinical development to clinical studies.
These may be disease or discipline-based but must
address major unanswered questions in the field and un-
met clinical needs.
3. Experience with and commitment to a team science
approach with basic and more applied scientists working
together to achieve translational goals.
4. Tangible evidence of a commitment to collaboration both
within the Cancer Centre’s own country and internation-
ally, as a single Centre usually will be less effective in
developing and testing new approaches that lead to
changes in clinical practice.
5. Establishment of shared resource facilities (Cores) to sup-
port the research Programmes.
6. National and international peer review systems (including
evaluation by funding and government bodies) assess the
Centre on a regular basis to helpmaintain and improve the
overall quality of the programmes, leadership, shared fa-
cilities (e.g. biospecimen banks) and research/clinical
studies.
7. Commitment to a program of training of new translational
scientists and re-training of established basic, clinical, or
population scientists who wish to redirect their careers
into translational cancer research.
8. Establishment of an up-to-date fully and clinically anno-
tated biospecimen bank (or banks) with an information
technology system or network for tracking specimens
and linkage to clinical outcome and follow-up data. To
optimize the impact of the bank, specimens should be
shared with other researchers or collaborators.
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 6 4 5e6 5 1 6499. Ability and commitment to perform hypothesis-driven
and hypothesis-generating clinical and population
studies.
10. Demonstration of a sufficient patient population to sup-
port bench to bedside studies in all the programmatic
areas cited. Smaller cancer units should collaborate in
their clinical trials in an effort to reach large enough
numbers of patients to render the outcomes of these
studies valid and effective.
11. Commitment to funding high-risk/high-reward projects to
seize new and exciting research opportunities.
12. A detailed demonstration of the ongoing ability and a
clearly articulated intention to leverage funding and/or re-
sources obtained as a result of an “excellent” designation.
13. Involvement of patient advocates in advisory committees.2. Pilot experience of the Excellence Designation
System in 3 European CCCs
Participants in the piloted CCCs, as well as the peer-reviewers/
experts, felt that the excellence criteria for CCCs in transla-
tional research were very helpful in identifying areas of exist-
ing excellence as well as areas for further improvement.Figure 1 e Examples of excellence idBelow we highlight relevant quotes from the pilot
participants.
“For us, to be designated as an Excellent CCC should not be
a mere honorific or demographic distinction, but should,
above all, induce and result in new translational research
missions, roles, and high value/high clinical impact discov-
eries for such institutes” Peer Reviewers.
“There is no need to be anxious about the detailed Excel-
lence Designation System even at the smaller and younger
institutes. Yes, it will likely identifyweaknesses. True, your
institute may not shine as brightly yet as some older insti-
tutes. But detection of the weaknesses may allow improve-
ment, and identification of the strengths may allow
networking with the best cancer centres in Europe.” Hel-
sinki University Central Hospital Cancer Center.
“Preparing for the pilot of European CCCs in translational
research helped us identify our strengths and weaknesses
and where translational research can contribute to better
treatment and care for cancer patients. The interaction
with and the feedback from the site visit committee were
essential and highly appreciated in this process. The pilot
hasstimulated internaldiscussion,whichwill lead to further
strengthening of our translational cancer researchentified in the European CCCs.
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 6 4 5e6 5 1650programme. Other Centres can benefit from the best prac-
tices being identified in this process.” Cambridge Cancer
Centre.
“A high level review such as this (but without a large
burden of paperwork) is useful in catalysing discussion
among colleagues as to the priorities and performance of
the Centre, and identifying things that need attention.
The discussionswith the panel were lively and to the point;
they reinforced some things we knew about but should
attend to, and highlighted new ones. The pilot was well de-
signed to elicit characteristics and metrics of the Centre
that are truly relevant and a reflection of excellence, rather
than the more usual measures of volume without exami-
nation of excellence. It will create a network of centres
where ideas and scientists can be shared making it ideal
for high quality collaborative science” The Netherlands
Cancer Institute.3. How can we ensure that these criteria are suitable
for identifying and improving excellence in translational
cancer research?
The EDS was developed based on multiple sources of evi-
dence: existing literature; expert opinion from inside and
outside Europe (from certain National Cancer Institute-
designated Comprehensive Cancer Centres in the US and
similar institutions in Canada and from the Cancer Research
UK assessment process); stakeholder views (researchers, cli-
nicians, managers and patient representatives across Europe)
through a survey and a focus group discussion; as well as re-
ports of existing national assessments for CCCs in Europe.
To our knowledge, this is the first systematic attempt to exclu-
sively focus on identifying and designating excellent perfor-
mance of CCCs in translational cancer research. We used
available evidence to develop and pilot these criteria. The
site visitors, the expert team and the involved institutions
were unanimous in their opinion that excellent performance
can be identified in CCCs using the EDS.
We feel that a flexible approach is needed to identify and
assess excellence that may also fall outside the scope of the
excellence criteria used. All piloted CCCs shared a strong
emphasis on the physician-scientists career. Similarly,
increasing the quality and number of academic trials and
making better use of different features of Information Tech-
nology were common opportunities in all CCCs (see Table 1
and Figure 1). Distinctive examples of strengths and opportu-
nities were also identified.
Outputs such as publication impact and citation are
certainly important. In our systematic literature review
(Rajan et al., 2012) we found process-related criteria to also
be suitable for performance assessment. The EDS focuses on
evaluating excellence based on key inputs (e.g. facilities and
human/financial resources), outputs (e.g. publications) and
outcomes (e.g. effect of innovations in addressing unmet clin-
ical needs and the patient/population impact) but also on
evaluating and improving the process of translationalresearch (e.g. creating a suitable environment for conducting
translational research).
Aristotle said: “We are what we repeatedly do. Excellence,
then, is not an act, but a habit”. Thus, excellent performance
of CCCs in translational research should be a habit, built
into the mind-sets of the CCCs rather than a one-time quali-
fying act for an assessment. Experts strongly believe that
CCCs should have a sustainable organisational culture of
excellence across the continuum of basic research, develop-
ment, education and patient care and connect all individual
parts in order to succeed. This starts with having a strong
organisational vision for translational research.4. Conclusion
The positive experience of the piloted European CCCs as well
as the acceptance of these excellence criteria among the EACS
membership and key international experts in oncology cause
us to believe that the EDS is sufficiently validated to be imple-
mented. We have applied available knowledge, existing evi-
dence and past experience of experts to develop and pilot
this system. Our experience has already shown that assess-
ment of translational research excellence can deliver positive
impacts and added value to future developments in oncology.
We conclude that this system is ready to be implemented
through European and international excellence initiatives in
translational cancer research. However, it will need close
monitoring to be further adapted to cover different ap-
proaches in developing and sustaining excellence during
and beyond implementation.Note
The peer-reviewers who piloted the EDS are: Prof. David Liv-
ingston MD, PhD (Dana-Farber/Harvard Cancer Center, USA),
Toby T. Hecht PhD (Translational Research Program, National
Cancer Institute, USA), Prof. Robert Bristow MD, PhD (Princess
Margaret Cancer Center, Canada), and Prof. Thomas Tursz
MD, PhD (Honorary Director Institut Gustave Roussy, France).
The review team was selected by the EACS.Appendix A.
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